CN113797215A - Composition containing pinoresinol and cycloolivil 9-glucoside and preparation method and application thereof - Google Patents
Composition containing pinoresinol and cycloolivil 9-glucoside and preparation method and application thereof Download PDFInfo
- Publication number
- CN113797215A CN113797215A CN202111013751.3A CN202111013751A CN113797215A CN 113797215 A CN113797215 A CN 113797215A CN 202111013751 A CN202111013751 A CN 202111013751A CN 113797215 A CN113797215 A CN 113797215A
- Authority
- CN
- China
- Prior art keywords
- cycloolivil
- parts
- pinoresinol
- glucoside
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- KCIQZCNOUZCRGH-VOBQZIQPSA-N Cycloolivil Chemical compound C1([C@@H]2[C@@H](CO)[C@](O)(CO)CC=3C=C(C(=CC=32)O)OC)=CC=C(O)C(OC)=C1 KCIQZCNOUZCRGH-VOBQZIQPSA-N 0.000 title claims abstract description 75
- KCIQZCNOUZCRGH-UHFFFAOYSA-N cycloolivil Natural products C1=2C=C(O)C(OC)=CC=2CC(O)(CO)C(CO)C1C1=CC=C(O)C(OC)=C1 KCIQZCNOUZCRGH-UHFFFAOYSA-N 0.000 title claims abstract description 75
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 title claims abstract description 53
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 235000007221 pinoresinol Nutrition 0.000 title claims abstract description 53
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 64
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 32
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 32
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229960001285 quercetin Drugs 0.000 claims abstract description 32
- 235000005875 quercetin Nutrition 0.000 claims abstract description 32
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims abstract description 31
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 31
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims abstract description 31
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims abstract description 31
- 229940074393 chlorogenic acid Drugs 0.000 claims abstract description 31
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims abstract description 31
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 31
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 22
- -1 guttiferol Chemical compound 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 67
- 239000000243 solution Substances 0.000 claims description 51
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 40
- 229930182490 saponin Natural products 0.000 claims description 40
- 150000007949 saponins Chemical class 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- 239000012153 distilled water Substances 0.000 claims description 28
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 20
- 238000010828 elution Methods 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- 239000011347 resin Substances 0.000 claims description 13
- 229920005989 resin Polymers 0.000 claims description 13
- 239000004094 surface-active agent Substances 0.000 claims description 13
- 238000001179 sorption measurement Methods 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 10
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 239000012535 impurity Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 238000002791 soaking Methods 0.000 claims description 9
- 229940083466 soybean lecithin Drugs 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 208000003947 Knee Osteoarthritis Diseases 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000003463 adsorbent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 claims description 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims 6
- BVHIKUCXNBQDEM-JSNMRZPZSA-N (3s,4r,5s)-5-(4-hydroxy-3-methoxyphenyl)-3-[(4-hydroxy-3-methoxyphenyl)methyl]-4-(hydroxymethyl)oxolan-3-ol Chemical compound C1=C(O)C(OC)=CC(C[C@]2(O)[C@@H]([C@H](OC2)C=2C=C(OC)C(O)=CC=2)CO)=C1 BVHIKUCXNBQDEM-JSNMRZPZSA-N 0.000 claims 1
- NYDZRKZVFLLTLO-UHFFFAOYSA-N Neoolivil Natural products C1=C(O)C(OC)=CC(C2C(C(CO)C(O2)C=2C=C(OC)C(O)=CC=2)CO)=C1 NYDZRKZVFLLTLO-UHFFFAOYSA-N 0.000 claims 1
- BVHIKUCXNBQDEM-UHFFFAOYSA-N Olivil Natural products C1=C(O)C(OC)=CC(CC2(O)C(C(OC2)C=2C=C(OC)C(O)=CC=2)CO)=C1 BVHIKUCXNBQDEM-UHFFFAOYSA-N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000008347 soybean phospholipid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 9
- 206010003246 arthritis Diseases 0.000 abstract description 7
- 241001421185 Anomis Species 0.000 abstract description 4
- 241001122767 Theaceae Species 0.000 description 58
- 241000700159 Rattus Species 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 206010042674 Swelling Diseases 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 210000000629 knee joint Anatomy 0.000 description 7
- 239000002994 raw material Substances 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 239000000899 Gutta-Percha Substances 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 241000195954 Lycopodium clavatum Species 0.000 description 2
- 240000000342 Palaquium gutta Species 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229920000588 gutta-percha Polymers 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- 240000002245 Acer pensylvanicum Species 0.000 description 1
- 235000006760 Acer pensylvanicum Nutrition 0.000 description 1
- 241000427159 Achyranthes Species 0.000 description 1
- 241000227129 Aconitum Species 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 240000004510 Agastache rugosa Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 235000017965 Asarum canadense Nutrition 0.000 description 1
- 244000189799 Asimina triloba Species 0.000 description 1
- 235000006264 Asimina triloba Nutrition 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 241000218158 Clematis Species 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 235000000385 Costus speciosus Nutrition 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000164480 Curcuma aromatica Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 241000241550 Cyathula Species 0.000 description 1
- 241000123589 Dipsacus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 208000010300 Genu Varum Diseases 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 235000015912 Impatiens biflora Nutrition 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010062061 Knee deformity Diseases 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- 206010061223 Ligament injury Diseases 0.000 description 1
- 206010072970 Meniscus injury Diseases 0.000 description 1
- 240000002624 Mespilus germanica Species 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 235000008898 Morinda citrifolia Nutrition 0.000 description 1
- 244000131360 Morinda citrifolia Species 0.000 description 1
- 235000008248 Morinda citrifolia var citrifolia Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 240000009022 Smilax rotundifolia Species 0.000 description 1
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 1
- 241000913745 Spatholobus Species 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 235000005155 Tanacetum balsamita Nutrition 0.000 description 1
- 241000606265 Valeriana jatamansi Species 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 235000014687 Zingiber zerumbet Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 244000195896 dadap Species 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000017524 noni Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000005528 popliteal cyst Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicines, and particularly relates to a composition containing pinoresinol and cycloolivil 9-glucoside, and a preparation method and application thereof. The composition comprises the following components: cycloolivil 9-glucoside, chlorogenic acid, pinoresinol, guttiferol, and quercetin. The composition can effectively improve the effect of the composition on treating the gonitis, has higher utilization rate of the medicine, effectively reduces the cost and reduces the side effect of the medicine.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a composition containing pinoresinol and cycloolivil 9-glucoside, and a preparation method and application thereof.
Background
Gonarthritis is a disorder that is based on a degenerative change of pathology. The symptoms of the middle-aged and the elderly are manifested as red and sore knee, pain in ascending and descending stairs, and soreness and discomfort of knee when sitting up and standing. There are also symptoms of swelling, ringing, fluid accumulation, etc., which can cause joint deformity and disability if the patient is not treated in time. Joint diseases such as gonarthromeningitis, ligament injury, meniscus injury, loose knee joint body, popliteal cyst, patellar malacia, goose foot bursitis, and genu varum are also commonly suffered at the knee joint part. For example, Chinese patent application CN201910540161.2 provides a traditional Chinese medicine preparation for treating knee osteoarthritis, which comprises the following traditional Chinese medicine raw materials in parts by weight: 15-20 parts of eucommia ulmoides, 15-20 parts of epimedium herb, 5-10 parts of teasel root, 20-30 parts of medicinal cyathula root, 5-10 parts of fructus psoraleae, 15-20 parts of notopterygium root, 5-10 parts of bighead atractylodes rhizome, 15-20 parts of acanthopanax bark, 10-20 parts of angelica, 2-5 parts of platycladi seed, 5-10 parts of cassia bark, 5-10 parts of lycopodium clavatum, 15-20 parts of curcuma zedoary, 5-10 parts of medlar, 5-10 parts of notopterygium root, 2-5 parts of liquorice, 5-10 parts of rhizoma atractylodis, 1-2 parts of wrinkled gianthyssop, 5-10 parts of salvia miltiorrhiza, 10-20 parts of oyster, 10-20 parts of radix angelicae pubescentis, 2-5 parts of coix seed, 5-10 parts of pawpaw and 2-5 parts of glabrous greenbrier rhizome. The preparation can effectively relieve pain of patients and can simultaneously increase bone density.
Chinese patent application CN201610170627.0 discloses a combined traditional Chinese medicine for treating gonarthritis, which has the following formula: 12-18 parts of raw common monkshood mother root, 12-18 parts of raw kusnezoff monkshood root, 12-18 parts of manchurian wildginger herb, 12-18 parts of peach kernel, 12-18 parts of twotooth achyranthes root, 16-24 parts of incised notopterygium rhizome and root, 22-28 parts of common clubmoss herb, 22-28 parts of medicinal indianmulberry root, 22-28 parts of clematis root, 22-28 parts of garden balsam stem, 22-28 parts of rhubarb, 22-28 parts of Szechuan lovage rhizome, 20-30 parts of Chinese angelica, 20-30 parts of suberect spatholobus stem, 20-30 parts of erythrina bark and 20-30 parts of mulberry twig. Has effects in expelling pathogenic wind, removing dampness, promoting blood circulation, activating collateral flow, relieving pain, promoting blood circulation, and relieving pain.
Most of the raw materials of the medicament in the prior art are more in variety, and the medicament has a certain effect of relieving the gonarthritis, but the utilization efficiency of the medicament is not effectively improved, the curative effect still needs to be improved, the interaction among the raw materials is unclear, and the side effect is greater in the using process of a patient.
The invention aims to provide a composition for treating gonitis, which can effectively improve the effect of the composition for treating gonitis, has higher utilization rate of medicines, effectively reduces the cost and reduces the side effects of the medicines.
Disclosure of Invention
In order to overcome the technical problems, the invention provides a composition containing pinoresinol and cycloolivil 9-glucoside, a preparation method and application thereof. The composition has good effect of treating the gonitis, and simultaneously, the utilization rate of the medicine is high, so that the cost is effectively reduced, and the side effect of the medicine is reduced.
In order to achieve the above purpose, the technical scheme provided by the invention is as follows:
a composition containing cycloolivil 9-glucoside comprises the following components: cycloolivil 9-glucoside, chlorogenic acid, pinoresinol, guttiferol, and quercetin.
Preferably, the composition containing the cycloolivil 9-glucoside comprises the following components in parts by weight: 5-20 parts of cycloolivil 9-glucoside, 1-10 parts of chlorogenic acid, 5-15 parts of pinoresinol, 1-5 parts of gutta alcohol and 1-5 parts of quercetin.
Preferably, the composition containing the cycloolivil 9-glucoside comprises the following components in parts by weight: 8-12 parts of cycloolivil 9-glucoside, 5-7 parts of chlorogenic acid, 7-11 parts of pinoresinol, 2-4 parts of gutta alcohol and 2-3 parts of quercetin.
Another object of the present invention is to provide a method for preparing the composition containing cycloolivil 9-glycoside, comprising the steps of:
(1) adding surfactant A into distilled water, heating, dissolving cycloolivil 9-glucoside, chlorogenic acid and pinoresinol in sequence, and stirring to obtain solution 1;
(2) adding surfactant B into distilled water, and adding gutta alcohol and quercetin to form solution 2;
(3) mixing the solution 1 and the solution 2, and stirring to obtain the composition containing the pinoresinol and the cycloolivil 9-glucoside.
Preferably, in the step (1), the surfactant a is any one or more of soybean lecithin, octyl- β -D-glucopyranoside, dodecyl- β -D-maltopyranoside and N-dodecyl-N-methylglucamide.
Preferably, in the step (1), the surfactant A is a mixture of N-dodecyl-N-methyl glucamide and soybean lecithin in a mass ratio of 4-6: 1.
Preferably, the addition amount of the surfactant A is 0.1-0.5% of the mass of the distilled water.
Preferably, the addition amount of the distilled water is 2-3 times of the total mass of the cycloolivil 9-glucoside, the chlorogenic acid and the pinoresinol.
Preferably, in step (1), the temperature of the heating is 30-45 ℃.
Preferably, the surfactant B is tea saponin, and the addition amount of the tea saponin is 0.1-1% of the total mass of the gutta alcohol and the quercetin.
Preferably, the preparation method of the tea saponin comprises the following steps:
pulverizing tea seed cake, soaking in hot water for extraction, filtering, treating the extractive solution with macroporous adsorbent resin, eluting with ethanol water solution, and drying to obtain tea saponin.
Preferably, the temperature of the hot water is 60-80 ℃, and the extraction time is 3-4 h.
Preferably, sodium carbonate is added in the extraction process, and the adding amount of the sodium carbonate is 5-10% of the mass of the tea seed cake.
Preferably, the macroporous adsorption resin is D3520 or D4006 type macroporous adsorption resin.
The specific process of the ethanol water solution elution is that 80-95% of ethanol water solution is used for eluting to remove impurities, 30-45% of ethanol is used for eluting and collecting eluent.
Preferably, the volume fraction of 80-95% has an elution rate of 1-3BV/h and is used in an amount of 1-2 BV.
Preferably, the elution rate of 30-45% by volume is 1-3BV/h, and the amount is 3-5 BV.
The invention also aims to provide application of the composition containing the pinoresinol and the cycloolivil 9-glucoside in preparing the knee osteoarthritis medicine.
The invention also aims to provide a preparation of the composition containing the pinoresinol and the cycloolivil 9-glucoside, wherein the preparation is granules, tablets, capsules or oral liquid.
Compared with the prior art, the invention has the technical advantages that:
(1) the composition containing pinoresinol and cycloolivil 9-glucoside provided by the invention has a good effect of treating knee osteoarthritis, and simultaneously has a good synergistic effect with chlorogenic acid, pinoresinol, guttapercha and quercetin.
(2) In the invention, the surfactant is added in the process of preparing the composition, so that the storage stability of the composition can be improved on one hand, and the stability of the drug effect can be improved on the other hand.
(3) The tea saponin is added in the preparation process, so that the stability of the composition can be effectively promoted, and the tea saponin can also be synergistically acted with the eucommia alcohol and the quercetin to promote the drug effect of the composition.
Detailed Description
The present invention will be described below with reference to specific examples to make the technical aspects of the present invention easier to understand and grasp, but the present invention is not limited thereto. The experimental methods described in the following examples are all conventional methods unless otherwise specified; the reagents and materials are commercially available, unless otherwise specified.
Example 1
The composition containing cycloolivil 9-glucoside comprises the following components in parts by weight: 12 parts of cycloolivil 9-glucoside, 7 parts of chlorogenic acid, 7 parts of pinoresinol, 4 parts of gutta alcohol and 2 parts of quercetin.
The preparation method of the composition containing the cycloolivil 9-glucoside comprises the following steps:
(1) distilled water which is 2 times of the total mass of the cycloolivil 9-glucoside, the chlorogenic acid and the pinoresinol is taken, and 0.3 wt% of distilled water with the mass ratio of 5: 1, heating the mixture of N-dodecyl-N-methyl glucamide and soybean lecithin to 40 ℃, dissolving cycloolivil 9-glucoside, chlorogenic acid and pinoresinol in the mixture in turn, and stirring the mixture to form a solution 1;
(2) adding tea saponin into distilled water, wherein the adding amount of the tea saponin is 0.3 wt% of the total mass of the gutta alcohol and the quercetin, and then adding the gutta alcohol and the quercetin to form a solution 2;
(3) mixing the solution 1 and the solution 2, and stirring to obtain the composition containing the pinoresinol and the cycloolivil 9-glucoside.
The preparation method of the tea saponin comprises the following steps: crushing tea seed cakes, adding the crushed tea seed cakes into hot water at 70 ℃, adding sodium carbonate with the mass of 6 wt% of the tea seed cakes, soaking and extracting for 3 hours, filtering, treating an extracting solution by using D3520 macroporous adsorption resin, eluting by using 2BV of ethanol aqueous solution with the volume fraction of 80%, and removing impurities, wherein the elution rate is 2 BV/h; eluting with 4BV of 35% ethanol at an elution rate of 2BV/h, and collecting the eluate; drying the eluent to obtain the tea saponin.
Example 2
The composition containing cycloolivil 9-glucoside comprises the following components in parts by weight: 5 parts of cycloolivil 9-glucoside, 5 parts of chlorogenic acid, 11 parts of pinoresinol, 2 parts of gutta alcohol and 1 part of quercetin.
The preparation method of the composition containing the cycloolivil 9-glucoside comprises the following steps:
(1) taking distilled water with the weight 3 times of the total weight of the cycloolivine 9-glucoside, the chlorogenic acid and the pinoresinol, adding 0.5 wt% of a mixture of N-dodecyl-N-methyl glucamide and soybean lecithin with the mass ratio of 4:1 into the distilled water, heating to 30 ℃, then sequentially dissolving the cycloolivine 9-glucoside, the chlorogenic acid and the pinoresinol in the mixture, and stirring to form a solution 1;
(2) adding tea saponin into distilled water, wherein the adding amount of the tea saponin is 0.1 percent of the total mass of the gutta alcohol and the quercetin, and then adding the gutta alcohol and the quercetin to form a solution 2;
(3) mixing the solution 1 and the solution 2, and stirring to obtain the composition containing the pinoresinol and the cycloolivil 9-glucoside.
The preparation method of the tea saponin comprises the following steps: crushing tea seed cakes, adding the crushed tea seed cakes into hot water at 60 ℃, adding sodium carbonate with the mass of 5 wt% of the tea seed cakes, soaking and extracting for 3 hours, filtering, treating an extracting solution by using D4006 type macroporous adsorption resin, eluting and removing impurities by using an ethanol aqueous solution with the volume fraction of 1BV being 95%, wherein the elution rate is 1 BV/h; eluting with 5BV of 45% ethanol at an elution rate of 1BV/h, and collecting the eluate; drying the eluent to obtain the tea saponin.
Example 3
The composition containing cycloolivil 9-glucoside comprises the following components in parts by weight: 20 parts of cycloolivil 9-glucoside, 10 parts of chlorogenic acid, 11 parts of pinoresinol, 5 parts of gutta alcohol and 5 parts of quercetin.
The preparation method of the composition containing the cycloolivil 9-glucoside comprises the following steps:
(1) taking distilled water 2-3 times of the total mass of cycloolivil 9-glucoside, chlorogenic acid and pinoresinol, adding 0.1 wt% of a mixture of N-dodecyl-N-methyl glucamide and soybean lecithin with the mass ratio of 6:1 into the distilled water, heating to 45 ℃, sequentially dissolving the cycloolivil 9-glucoside, the chlorogenic acid and the pinoresinol in the mixture, and stirring to form a solution 1;
(2) adding tea saponin into distilled water, wherein the adding amount of the tea saponin is 1 percent of the total mass of the gutta alcohol and the quercetin, and then adding the gutta alcohol and the quercetin to form a solution 2;
(3) mixing the solution 1 and the solution 2, and stirring to obtain the composition containing the pinoresinol and the cycloolivil 9-glucoside.
The preparation method of the tea saponin comprises the following steps: crushing tea seed cakes, adding the crushed tea seed cakes into hot water at 80 ℃, adding sodium carbonate with the mass of 10 wt% of the tea seed cakes, soaking and extracting for 4 hours, filtering, treating an extracting solution by using D4006 type macroporous adsorption resin, eluting by using 2BV of ethanol aqueous solution with the volume fraction of 80%, and removing impurities, wherein the elution rate is 3 BV/h; eluting with 30% ethanol of 3BV at an elution rate of 3BV/h, and collecting the eluate; drying the eluent to obtain the tea saponin.
Example 4
The composition containing cycloolivil 9-glucoside comprises the following components in parts by weight: 12 parts of cycloolivil 9-glucoside, 7 parts of chlorogenic acid, 7 parts of pinoresinol, 4 parts of gutta alcohol and 2 parts of quercetin.
The preparation method of the composition containing the cycloolivil 9-glucoside comprises the following steps:
(1) adding 0.3 wt% of soybean lecithin into distilled water which is 2 times of the total mass of cycloolivil 9-glucoside, chlorogenic acid and pinoresinol, heating to 40 ℃, dissolving the cycloolivil 9-glucoside, the chlorogenic acid and the pinoresinol in turn, and stirring to form a solution 1;
(2) adding tea saponin into distilled water, wherein the adding amount of the tea saponin is 0.3 wt% of the total mass of the gutta alcohol and the quercetin, and then adding the gutta alcohol and the quercetin to form a solution 2;
(3) mixing the solution 1 and the solution 2, and stirring to obtain the composition containing the pinoresinol and the cycloolivil 9-glucoside.
The preparation method of the tea saponin comprises the following steps: crushing tea seed cakes, adding the crushed tea seed cakes into hot water at 70 ℃, adding sodium carbonate with the mass of 6 wt% of the tea seed cakes, soaking and extracting for 3 hours, filtering, treating an extracting solution by using D3520 macroporous adsorption resin, eluting by using 2BV of ethanol aqueous solution with the volume fraction of 80%, and removing impurities, wherein the elution rate is 2 BV/h; eluting with 4BV of 35% ethanol at an elution rate of 2BV/h, and collecting the eluate; drying the eluent to obtain the tea saponin.
Example 5
The composition containing cycloolivil 9-glucoside comprises the following components in parts by weight: 12 parts of cycloolivil 9-glucoside, 7 parts of chlorogenic acid, 7 parts of pinoresinol, 4 parts of gutta alcohol and 2 parts of quercetin.
The preparation method of the composition containing the cycloolivil 9-glucoside comprises the following steps:
(1) taking distilled water 2 times of the total mass of cycloolivil 9-glucoside, chlorogenic acid and pinoresinol, adding 0.3 wt% of dodecyl-beta-D-maltopyranoside into the distilled water, heating to 40 ℃, dissolving the cycloolivil 9-glucoside, the chlorogenic acid and the pinoresinol in turn, and stirring to form a solution 1;
(2) adding tea saponin into distilled water, wherein the adding amount of the tea saponin is 0.3 wt% of the total mass of the gutta alcohol and the quercetin, and then adding the gutta alcohol and the quercetin to form a solution 2;
(3) mixing the solution 1 and the solution 2, and stirring to obtain the composition containing the pinoresinol and the cycloolivil 9-glucoside.
The preparation method of the tea saponin comprises the following steps: crushing tea seed cakes, adding the crushed tea seed cakes into hot water at 70 ℃, adding sodium carbonate with the mass of 6 wt% of the tea seed cakes, soaking and extracting for 3 hours, filtering, treating an extracting solution by using D3520 macroporous adsorption resin, eluting by using 2BV of ethanol aqueous solution with the volume fraction of 80%, and removing impurities, wherein the elution rate is 2 BV/h; eluting with 4BV of 35% ethanol at an elution rate of 2BV/h, and collecting the eluate; drying the eluent to obtain the tea saponin.
Comparative example 1
The difference compared to example 1 is the replacement of quercetin with gutta percha alcohol.
The composition containing cycloolivil 9-glucoside comprises the following components in parts by weight: 12 parts of cycloolivil 9-glucoside, 7 parts of chlorogenic acid, 7 parts of pinoresinol and 6 parts of gutta alcohol.
The preparation method of the composition containing the cycloolivil 9-glucoside comprises the following steps:
(1) distilled water which is 2 times of the total mass of the cycloolivil 9-glucoside, the chlorogenic acid and the pinoresinol is taken, and 0.3 wt% of distilled water with the mass ratio of 5: 1, heating the mixture of N-dodecyl-N-methyl glucamide and soybean lecithin to 40 ℃, dissolving cycloolivil 9-glucoside, chlorogenic acid and pinoresinol in the mixture in turn, and stirring the mixture to form a solution 1;
(2) adding tea saponin into distilled water, wherein the addition amount of the tea saponin is 0.3 wt% of the total mass of the gutta alcohol, and then adding the gutta alcohol to form a solution 2;
(3) mixing the solution 1 and the solution 2, and stirring to obtain the composition containing the pinoresinol and the cycloolivil 9-glucoside.
The preparation method of the tea saponin is the same as that of the example 1.
Comparative example 2
The difference compared to example 1 is the replacement of chlorogenic acid by citric acid.
The composition containing cycloolivil 9-glucoside comprises the following components in parts by weight: 12 parts of cycloolivil 9-glucoside, 7 parts of citric acid, 7 parts of pinoresinol, 4 parts of gutta alcohol and 2 parts of quercetin.
The preparation method of the composition containing the cycloolivil 9-glucoside comprises the following steps:
(1) distilled water which is 2 times of the total mass of the cycloolivil 9-glucoside, the citric acid and the pinoresinol is taken, and 0.3 wt% of distilled water with the mass ratio of 5: 1, heating the mixture of N-dodecyl-N-methyl glucamide and soybean lecithin to 40 ℃, dissolving cycloolivil 9-glucoside, citric acid and pinoresinol in the mixture in turn, and stirring the mixture to form a solution 1;
(2) adding tea saponin into distilled water, wherein the adding amount of the tea saponin is 0.3 wt% of the total mass of the gutta alcohol and the quercetin, and then adding the gutta alcohol and the quercetin to form a solution 2;
(3) mixing the solution 1 and the solution 2, and stirring to obtain the composition containing the pinoresinol and the cycloolivil 9-glucoside.
The preparation method of the tea saponin comprises the following steps: crushing tea seed cakes, adding the crushed tea seed cakes into hot water at 70 ℃, adding sodium carbonate with the mass of 6 wt% of the tea seed cakes, soaking and extracting for 3 hours, filtering, treating an extracting solution by using D3520 macroporous adsorption resin, eluting by using 2BV of ethanol aqueous solution with the volume fraction of 80%, and removing impurities, wherein the elution rate is 2 BV/h; eluting with 4BV of 35% ethanol at an elution rate of 2BV/h, and collecting the eluate; drying the eluent to obtain the tea saponin.
Comparative example 3
Compared with example 1, the difference lies in the preparation method of the tea saponin.
A composition containing cycloolivil 9-glycoside is prepared in the same manner as in example 1.
The preparation method of the composition containing the cycloolivil 9-glucoside comprises the following steps:
(1) - (3) same as in example 1.
The preparation method of the tea saponin comprises the following steps:
crushing tea seed cakes, soaking and extracting the tea seed cakes in hot water at 70 ℃ for 3 hours, filtering, treating an extracting solution by using D3520 type macroporous adsorption resin, eluting and removing impurities by using an ethanol water solution with the volume fraction of 2BV being 90% according to the elution rate of 2BV/h, eluting and collecting eluent by using ethanol with the volume fraction of 4BV being 40% according to the elution rate of 2BV/h, and drying to obtain the tea saponin.
1. Experiment of anti-inflammatory effect of xylene on swelling of auricle of rat
60 SPF grade healthy male Wistar rats with the body weight of 200 +/-20 g are divided into 10 groups, and 6 rats in each group are respectively a blank group, a positive drug group, examples 1-5 groups and comparative examples 1-3 groups. Xylene is smeared on the two sides of the right ear of each rat, 50 ul/mouse, and the drug is administrated according to the following groups after 30 min: blank group was not given any drug; the compositions prepared in the corresponding groups are respectively administered to the groups 1 to 5 and the groups 1 to 3 according to the effective content of 0.5mg/kg, and the compositions are properly massaged after the right ears of rats are smeared on the two sides to promote the absorption of the medicaments; the positive drug group was prepared by applying commercially available loxoprofen sodium gel ointment (prepared in Jiedian of Hunan) on both sides of the rat's right ear and then massaging the rat's right ear appropriately to promote drug absorption. After 1h, the animals were sacrificed by cervical dislocation, round ears were respectively punched at the same positions by using a 6mm diameter punch at both sides of the ears, the mass was weighed by using a precision torsion balance, and the swelling degree and swelling rate were calculated, and the results are shown in table 1.
TABLE 1 swelling degree and swelling Rate data
In the same list, the different symbols have significant difference, and P is less than 0.05.
As can be seen from Table 1, the compositions provided in examples 1 to 5 and comparative examples 1 to 3 reduced swelling of auricles of rats caused by xylene compared with the blank group, which indicates that the composition provided by the present invention has a superior anti-inflammatory effect. Meanwhile, the raw material composition and the preparation method of the composition have great influence on the effect of the composition.
2. Rat knee osteoarthritis model experiment
60 SD rats with a body weight of 200 + -20 g were randomly divided into 10 groups of 6 rats, namely a normal group, a model group, examples 1-5 groups and a comparative example-3 group.
Except for the normal group, rats replicated the KOA model by injecting papain through the joint cavity; the rats were prepared and sterilized, and after shaving the right anterior knee joint and the lower hair, the skin was sterilized with 75% ethanol, and then 0.2mL of 4% papain solution was injected into the right anterior knee joint cavity, once every 2 days, for 2 weeks. After 14d, successful replication was demonstrated if the following symptoms were observed in the rats: red swelling and pain of the right anterior knee joint accompanied by swelling of soft tissue or the appearance of fluid accumulation; stiffness and limited movement of the right anterior knee joint and surrounding areas; the pathological examination result of the right front knee joint shows that a large amount of exudates appear in the joint cavity; the cartilage surface is not smooth, and the arthritic pathology such as synovial hyperplasia or adhesion exists. On day 2 after successful molding, examples 1-5 and comparison were performed except that the normal and model groups were gazed with physiological salineExamples 1-3 groups of rats were administered the composition prepared in the corresponding group, and the composition was administered to the rats by gavage at a dose of 10mg/kg/d for intervention, and femoral artery blood was collected at 1500 rpm-min from each group of rats 4 weeks after the intervention-1Centrifuging for 10min, collecting serum, and detecting IL-6 (interleukin-6), TNF-alpha (tumor necrosis factor-alpha), and IL-1 beta (interleukin-1 beta) levels by ELISA (enzyme-linked immunosorbent assay kit manufacturer: Wuhan Elirei Biotech). The results are shown in Table 2.
TABLE 2 levels of inflammatory factors
| Test group | IL-6(ng·L-1) | TNF-α(ng·L-1) | IL-1β(ng·L-1) |
| Blank group | 18.32±2.37a | 22.15±6.14f | 6.01±1.09* |
| Model set | 44.26±4.51b | 41.34±4.11g | 12.65±2.34# |
| Example 1 | 23.57±5.34c | 25.43±3.57h | 7.46±0.87△ |
| Example 2 | 24.61±3.08c | 25.69±8.21h | 7.29±1.54△ |
| Example 3 | 23.68±1.55c | 26.07±6.47h | 7.54±2.05△ |
| Example 4 | 30.25±2.67d | 28.34±5.22h | 8.02±3.11▼ |
| Example 5 | 31.08±3.26d | 29.10±4.28h | 8.71±2.62▼ |
| Comparative example 1 | 34.53±6.64e | 33.76±9.14i | 10.89±1.03◇ |
| Comparative example 2 | 37.28±4.09e | 36.21±5.67i | 11.32±5.43◇ |
| Comparative example 3 | 33.56±5.12e | 31.43±4.39i | 9.86±2.19◇ |
In the same list, the different letters or symbols have significant difference, and P is less than 0.05.
As can be seen from Table 2, the compositions provided in examples 1 to 5 and comparative examples 1 to 3 were effective in intervening serum inflammatory factor levels, compared to the blank group, indicating that the composition provided by the present invention has a superior effect of treating knee osteoarthritis. Meanwhile, the raw material composition and the preparation method of the composition have great influence on the effect of the composition.
The above detailed description is specific to one possible embodiment of the present invention, and the embodiment is not intended to limit the scope of the present invention, and all equivalent implementations or modifications without departing from the scope of the present invention should be included in the technical scope of the present invention.
Claims (10)
1. A composition containing cycloolivil 9-glucoside comprises the following components: cycloolivil 9-glucoside, chlorogenic acid, pinoresinol, guttiferol, and quercetin.
2. The cycloolivil 9-glycoside-containing composition according to claim 1, comprising the following components in parts by weight: 5-20 parts of cycloolivil 9-glucoside, 1-10 parts of chlorogenic acid, 5-15 parts of pinoresinol, 1-5 parts of gutta alcohol and 1-5 parts of quercetin.
3. The cycloolivil 9-glycoside-containing composition according to claim 1, comprising the following components in parts by weight: 8-12 parts of cycloolivil 9-glucoside, 5-7 parts of chlorogenic acid, 7-11 parts of pinoresinol, 2-4 parts of gutta alcohol and 2-3 parts of quercetin.
4. A process for the preparation of a cycloolivil 9-glycoside-containing composition according to any one of claims 1 to 3, comprising the following steps:
(1) adding surfactant A into distilled water, heating, dissolving cycloolivil 9-glucoside, chlorogenic acid and pinoresinol in sequence, and stirring to obtain solution 1;
(2) adding surfactant B into distilled water, and adding gutta alcohol and quercetin to form solution 2;
(3) and mixing the solution 1 and the solution 2, and stirring.
5. The method for preparing a cyclic olivil 9-glycoside-containing composition according to claim 4, wherein in step (1), the surfactant A is any one or more of soybean lecithin, octyl- β -D-glucopyranoside, dodecyl- β -D-maltopyranoside and N-dodecyl-N-methylglucamide; the addition amount of the surfactant A is 0.1-0.5% of the mass of the distilled water; the addition amount of the distilled water is 2-3 times of the total mass of the cycloolivil 9-glucoside, the chlorogenic acid and the pinoresinol.
6. The method for preparing the composition containing cycloolivil 9-glycoside according to claim 4, wherein in step (1), the surfactant A is a mixture of N-dodecyl-N-methylglucamide and soya lecithin in a mass ratio of 4-6: 1.
7. The method of claim 4, wherein the surfactant B is tea saponin, and the amount of tea saponin added is 0.1-1% of the total weight of the gutta alcohol and quercetin.
8. The method of claim 7, wherein the tea saponin is prepared by the steps of: pulverizing tea seed cake, soaking in hot water for extraction, filtering, treating the extractive solution with macroporous adsorbent resin, eluting with ethanol water solution, and drying to obtain tea saponin;
preferably, sodium carbonate is added in the extraction process, and the adding amount of the sodium carbonate is 5-10% of the mass of the tea seed cake;
preferably, the macroporous adsorption resin is D3520 or D4006 type macroporous adsorption resin;
preferably, the specific process of the ethanol aqueous solution elution is that the ethanol aqueous solution with the volume fraction of 80-95% is used for eluting to remove impurities, then 30-45% ethanol is used for eluting and collecting the eluent.
9. Use of a composition containing pinoresinol and cycloolivil 9-glycoside according to any one of claims 1 to 3 or a composition containing pinoresinol and cycloolivil 9-glycoside prepared by the preparation method according to any one of claims 4 to 8 for the preparation of a medicament for treating knee osteoarthritis.
10. The preparation of the composition containing pinoresinol and cycloolivil 9-glycoside according to any one of claims 1 to 3 or the composition containing pinoresinol and cycloolivil 9-glycoside prepared by the preparation method according to any one of claims 4 to 8, wherein the preparation is granules, tablets, capsules or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111013751.3A CN113797215B (en) | 2021-08-31 | 2021-08-31 | Composition containing pinoresinol and cycloolivil 9-glycoside and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111013751.3A CN113797215B (en) | 2021-08-31 | 2021-08-31 | Composition containing pinoresinol and cycloolivil 9-glycoside and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113797215A true CN113797215A (en) | 2021-12-17 |
| CN113797215B CN113797215B (en) | 2023-11-24 |
Family
ID=78894484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111013751.3A Active CN113797215B (en) | 2021-08-31 | 2021-08-31 | Composition containing pinoresinol and cycloolivil 9-glycoside and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113797215B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114748132A (en) * | 2022-03-01 | 2022-07-15 | 四川大学华西医院 | Clinical special episome remove device of orthopedics |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105859804A (en) * | 2016-04-27 | 2016-08-17 | 江西普正制药有限公司 | Eucommia ulmoides extract as well as preparation method and application thereof |
-
2021
- 2021-08-31 CN CN202111013751.3A patent/CN113797215B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105859804A (en) * | 2016-04-27 | 2016-08-17 | 江西普正制药有限公司 | Eucommia ulmoides extract as well as preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 张涛: ""基于网络药理学和分子对接研究牛膝_杜仲药对治疗膝骨性关节炎的作用机制"", 《中成药》 * |
| 王金兰等: ""柳蒿化学成分研究"", 《中草药》 * |
| 赵金龙等: ""基于信号通路的中药有效成分治疗骨质疏松机制研究"", 《中草药》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114748132A (en) * | 2022-03-01 | 2022-07-15 | 四川大学华西医院 | Clinical special episome remove device of orthopedics |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113797215B (en) | 2023-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6238707B1 (en) | Herbal hormone balance composition | |
| CN102178895A (en) | Chinese medicine composition for treating orthopedic disorders and preparation method thereof | |
| CN103751310A (en) | External traditional Chinese medicinal preparation for treating fasciitis and preparation method thereof | |
| CN104013929B (en) | Rheumatism pain relief medicine for treating rheumatic arthritis and rheumatoid arthritis and preparation method thereof | |
| CN113797215B (en) | Composition containing pinoresinol and cycloolivil 9-glycoside and preparation method and application thereof | |
| GB2581592A (en) | Preparation procedure for panax notoginseng medicinal liquor for oral administration for treating rheumatic ostalgia | |
| WO2021062888A1 (en) | Complex composition with function of promoting bone and joint health and application thereof | |
| CN104474404A (en) | Compound suppositorycontrollinginfectionof immunodeficiency patient | |
| CN112704696B (en) | Traditional Chinese medicine composition for treating rhinitis | |
| CN108210651B (en) | A natural medicinal composition for treating diabetic nephropathy, and its preparation method | |
| CN111643540A (en) | Eucommia ulmoides extract for treating lumbar muscle strain and preparation method thereof | |
| CN109876127B (en) | Blood-nourishing angelica sinensis capsule and preparation method thereof | |
| CN113368145A (en) | Traditional Chinese medicine composition and health-care food preparation for enhancing immunity | |
| CN111084878A (en) | Biological medicine and medical total nutrient food for lung and respiratory system diseases and preparation method thereof | |
| CN106983813B (en) | A pharmaceutical composition for treating lumbago and preparation method thereof | |
| CN105902867B (en) | A herbal composition for reducing hypertension, hyperglycemia and hyperlipidemia, and its preparation method | |
| CN108310169A (en) | Pharmaceutical composition and preparation method thereof for preventing osteoarthritis | |
| CN116159098B (en) | Composition for preventing and treating degenerative osteoarthritis lesions | |
| CN114632127B (en) | Traditional Chinese medicine composition and preparation for treating pediatric jaundice as well as preparation method and application of traditional Chinese medicine composition and preparation | |
| CN116549522B (en) | Application of traditional Chinese medicine composition in gout | |
| CN113813344B (en) | Composition for treating joint pain and mastitis of lying-in women and application thereof | |
| CN114470121B (en) | Medicine for treating osteoarthritis and preparation method thereof | |
| CN112603964A (en) | Medicine bag for relieving arthralgia | |
| CN116603045A (en) | External plaster for relieving rheumatic leg pain and preparation method thereof | |
| CN103768251B (en) | A kind of medicine killed virus in blood cell, improve human antibody's immunizing power |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |